gliclazide has been researched along with Cardiovascular Diseases in 33 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
Excerpt | Relevance | Reference |
---|---|---|
"High blood glucose level, lipid profile disturbances and plasma homocysteine (Hcy) are important risk factors for cardiovascular diseases in patients with type 2 diabetes." | 5.20 | Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. ( Abd-Allah, GM; Hassan, MH, 2015) |
"As compared with the patients receiving insulin monotherapy, the patients taking metformin alone or in combination showed a more effective recovery of carbohydrate and lipid metabolic disturbances, diminished insulin resistance (IR), lowered blood pressure and albuminuria, reduced diastolic dysfunction, and a smaller cardiovascular risk." | 5.14 | [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010) |
"Included were randomized studies of at least 12 weeks duration with the following outcomes: HbA1c change, incidence of severe hypoglycemia, weight change, cardiovascular events and/or mortality when comparing gliclazide with other oral blood glucose lowering drugs." | 4.90 | Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. ( Bilo, HJ; de Bock, GH; Gans, RO; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; van Dijk, PR; van Hateren, KJ, 2014) |
"Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
"Treatment with glibenclamide could be associated with higher mortality for cardiovascular diseases and malignancies, in comparison with gliclazide." | 3.74 | Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. ( Balzi, D; Barchielli, A; Buiatti, E; Lamanna, C; Mannucci, E; Marchionni, N; Masotti, G; Monami, M, 2007) |
"Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes." | 2.94 | The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020) |
"Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes." | 2.75 | Severe hypoglycemia and risks of vascular events and death. ( Billot, L; Chalmers, J; de Galan, BE; Grobbee, DE; Heller, S; Kengne, AP; Li, Q; MacMahon, S; Marre, M; Neal, B; Ninomiya, T; Patel, A; Woodward, M; Zoungas, S, 2010) |
"In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events." | 2.75 | Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. ( Batty, GD; Chalmers, J; Czernichow, S; de Galan, BE; Hamet, P; Harrap, SB; Huxley, R; Li, Q; Neal, B; Patel, A; Poulter, N; Woodward, M; Zoungas, S, 2010) |
"In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain." | 2.73 | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ( Billot, L; Bompoint, S; Chalmers, J; Cooper, M; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Joshi, R; Liu, L; MacMahon, S; Mancia, G; Marre, M; Mogensen, CE; Neal, B; Pan, C; Patel, A; Poulter, N; Rodgers, A; Travert, F; Williams, B; Woodward, M, 2008) |
"The primary aim must be the treatment of the insulin resistance." | 2.43 | [Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. ( Schumm-Draeger, PM, 2005) |
"Gliclazide is a second-generation sulfonylurea that is widely used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)." | 2.38 | Gliclazide: metabolic and vascular effects--a perspective. ( Alberti, KG; Johnson, AB; Taylor, R, 1992) |
"A post hoc analysis of patients with type 2 diabetes followed by the ADVANCE-ON (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation - Observational Study)." | 1.72 | Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes. ( Chalmers, J; Hamet, P; Harrap, S; Harris, K; Mancia, G; Poulter, N; Rodgers, A; Wang, N; Williams, B; Woodward, M; Zoungas, S, 2022) |
"Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues." | 1.51 | Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019) |
"The objective of this study was to determine if there is a dose-response relationship between sulfonylureas and major adverse cardiovascular events (MACE)." | 1.43 | Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. ( Abdelmoneim, AS; Eurich, DT; Qiu, W; Senthilselvan, A; Simpson, SH, 2016) |
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes." | 1.43 | Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. ( Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016) |
"In older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae." | 1.42 | Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. ( Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH, 2015) |
"gliclazide treatment." | 1.35 | Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. ( Khalangot, M; Kovtun, V; Kravchenko, V; Tronko, M, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (9.09) | 18.2507 |
2000's | 8 (24.24) | 29.6817 |
2010's | 18 (54.55) | 24.3611 |
2020's | 4 (12.12) | 2.80 |
Authors | Studies |
---|---|
Wang, N | 1 |
Harris, K | 1 |
Hamet, P | 5 |
Harrap, S | 5 |
Mancia, G | 4 |
Poulter, N | 7 |
Williams, B | 3 |
Zoungas, S | 7 |
Woodward, M | 9 |
Chalmers, J | 9 |
Rodgers, A | 2 |
Kalra, S | 1 |
Lee, AK | 1 |
Wang, D | 1 |
Ohkuma, T | 2 |
Warren, B | 1 |
Sharrett, AR | 1 |
Marre, M | 4 |
Mcevoy, JW | 1 |
Selvin, E | 1 |
Tian, J | 1 |
Cooper, M | 3 |
Wang, JG | 1 |
Douros, A | 1 |
Yin, H | 1 |
Yu, OHY | 1 |
Filion, KB | 1 |
Azoulay, L | 1 |
Suissa, S | 1 |
Huang, HK | 1 |
Yeh, JI | 1 |
Bo, S | 1 |
Castiglione, A | 1 |
Ghigo, E | 1 |
Gentile, L | 1 |
Durazzo, M | 1 |
Cavallo-Perin, P | 1 |
Ciccone, G | 1 |
Konig, M | 1 |
Lamos, EM | 1 |
Stein, SA | 1 |
Davis, SN | 1 |
Landman, GW | 1 |
de Bock, GH | 1 |
van Hateren, KJ | 1 |
van Dijk, PR | 1 |
Groenier, KH | 1 |
Gans, RO | 1 |
Houweling, ST | 1 |
Bilo, HJ | 1 |
Kleefstra, N | 1 |
Erem, C | 1 |
Ozbas, HM | 1 |
Nuhoglu, I | 1 |
Deger, O | 1 |
Civan, N | 1 |
Ersoz, HO | 1 |
van der Leeuw, J | 2 |
Visseren, FL | 2 |
Kengne, AP | 3 |
van der Graaf, Y | 2 |
Glasziou, P | 2 |
MacMahon, S | 3 |
Grobbee, DE | 3 |
Mogensen, UM | 1 |
Andersson, C | 1 |
Fosbøl, EL | 1 |
Schramm, TK | 1 |
Vaag, A | 1 |
Scheller, NM | 1 |
Torp-Pedersen, C | 1 |
Gislason, G | 1 |
Køber, L | 1 |
Huang, Y | 1 |
Abdelmoneim, AS | 3 |
Light, P | 1 |
Qiu, W | 2 |
Simpson, SH | 3 |
Hassan, MH | 1 |
Abd-Allah, GM | 1 |
Hirakawa, Y | 1 |
Matthews, DR | 1 |
Patel, A | 4 |
Grobbee, R | 1 |
Jardine, M | 1 |
Eurich, DT | 1 |
Senthilselvan, A | 1 |
Heller, S | 3 |
Neal, B | 3 |
Billot, L | 2 |
Grobbee, D | 1 |
Liu, L | 1 |
Mogensen, CE | 1 |
Pan, C | 1 |
Bompoint, S | 1 |
de Galan, BE | 3 |
Joshi, R | 1 |
Travert, F | 1 |
Khalangot, M | 1 |
Tronko, M | 1 |
Kravchenko, V | 1 |
Kovtun, V | 1 |
Kassem, SA | 1 |
Raz, I | 1 |
Onuchin, SG | 1 |
Elsukova, OS | 1 |
Solov'ev, OV | 1 |
Onuchina, EL | 1 |
Bloomgarden, Z | 1 |
Li, Q | 2 |
Ninomiya, T | 1 |
Batty, GD | 1 |
Czernichow, S | 1 |
Huxley, R | 1 |
Harrap, SB | 1 |
Hasenbank, SE | 1 |
Seubert, JM | 1 |
Brocks, DR | 1 |
Light, PE | 1 |
Avogaro, A | 1 |
Khan, M | 1 |
Xu, Y | 1 |
Edwards, G | 1 |
Urquhart, R | 1 |
Mariz, S | 1 |
Schumm-Draeger, PM | 1 |
Betteridge, DJ | 1 |
Vergès, B | 1 |
Monami, M | 1 |
Balzi, D | 1 |
Lamanna, C | 1 |
Barchielli, A | 1 |
Masotti, G | 1 |
Buiatti, E | 1 |
Marchionni, N | 1 |
Mannucci, E | 1 |
Page, RC | 1 |
Harnden, KE | 1 |
Walravens, NK | 1 |
Onslow, C | 1 |
Sutton, P | 1 |
Levy, JC | 1 |
Hockaday, DT | 1 |
Turner, RC | 1 |
Cathelineau, G | 1 |
de Champvallins, M | 1 |
Bouallouche, A | 1 |
Lesobre, B | 1 |
Alberti, KG | 1 |
Johnson, AB | 1 |
Taylor, R | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286] | 8,494 participants (Actual) | Observational | 2010-01-31 | Completed | |||
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572] | 200 participants (Anticipated) | Observational | 2012-01-31 | Active, not recruiting | |||
Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891] | 160 participants (Actual) | Interventional | 2013-12-31 | Active, not recruiting | |||
Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559] | Phase 4 | 135 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632] | Phase 3 | 104 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309] | 465 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197] | Phase 2 | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation[NCT01123122] | 0 participants (Actual) | Interventional | 2011-09-30 | Withdrawn | |||
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
Intervention | percentage (Mean) |
---|---|
Insulin Glargine, Metformin, Exenatide | -2.43 |
Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
Intervention | % of HbA1C (Mean) |
---|---|
Insulin Glargine, Metformin, Exenatide | 7.1 |
Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
Intervention | Participants (Count of Participants) |
---|---|
Insulin Glargine, Metformin, Exenatide | 0 |
Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
Intervention | kg (Mean) |
---|---|
Insulin Glargine, Metformin, Exenatide | -4.8 |
Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks
Intervention | µg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 8.4 |
The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
Intervention | mmol/L (Median) |
---|---|
Sitagliptin | -0.2 |
Gliclazide | -0.1 |
The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
Intervention | mmHg (Median) |
---|---|
Sitagliptin | 4 |
Gliclazide | -9 |
The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
Intervention | mmol/L (Median) |
---|---|
Sitagliptin | 0.1 |
Gliclazide | -0.1 |
Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks
Intervention | score on a scale (Median) |
---|---|
Sitagliptin | 3 |
Gliclazide | 1.8 |
Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks
Intervention | score on a scale (Median) |
---|---|
Sitagliptin | 9.5 |
Gliclazide | 9.4 |
The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
Intervention | kg (Median) |
---|---|
Sitagliptin | -0.5 |
Gliclazide | -0.6 |
Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
Intervention | dCt (Median) |
---|---|
Gliclazide | -1.12 |
Sitagliptin | 0 |
Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
Intervention | dCt (Median) |
---|---|
Sitagliptin | 3.41 |
Gliclazide | 2.09 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | -0.07 |
Gliclazide | 0.43 |
"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 0 |
"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks
Intervention | Participants (Count of Participants) |
---|---|
Sitagliptin | 6 |
Gliclazide | 10 |
"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks
Intervention | score on a scale (Median) | ||||
---|---|---|---|---|---|
DLQI | HAQ-8 | HADS Anxiety | HADS Depression | EQ-5D | |
Gliclazide | -1.0 | 0.0 | 0 | 0 | -0.2 |
Sitagliptin | 0.0 | 0.0 | -1 | 0 | 0 |
"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
PASI 50 | PASI 75 | PASI 90 | |
Gliclazide | 1 | 0 | 0 |
Sitagliptin | 1 | 0 | 0 |
7 reviews available for gliclazide and Cardiovascular Diseases
Article | Year |
---|---|
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 2013 |
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
Topics: Administration, Oral; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2014 |
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetic Angiopathies; Disease Progression; Enzyme In | 2009 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohe | 2012 |
Treating diabetes today with gliclazide MR: a matter of numbers.
Topics: Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Ne | 2012 |
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gli | 2005 |
Gliclazide: metabolic and vascular effects--a perspective.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gliclazide; Humans; Insul | 1992 |
13 trials available for gliclazide and Cardiovascular Diseases
Article | Year |
---|---|
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combin | 2020 |
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2 | 2020 |
Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypogly | 2014 |
Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mell | 2015 |
Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2015 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
Topics: Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug The | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-A | 2010 |
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2004 |
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2005 |
'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance.
Topics: Adolescent; Adult; Body Weight; Cardiovascular Diseases; Double-Blind Method; Exercise Therapy; Glic | 1993 |
Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
Topics: Aged; Albuminuria; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Protocols; Cohort St | 1997 |
13 other studies available for gliclazide and Cardiovascular Diseases
Article | Year |
---|---|
Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes.
Topics: Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gliclazide; Heart Disease Risk F | 2022 |
ADVANCE to ADVANCE-ON: Unfolding the "Legacy Story" in Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Prospective Studies | 2023 |
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus | 2017 |
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2019 |
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confounding Factors, Epidemiol | 2013 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular | 2015 |
Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2016 |
Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Re | 2016 |
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations | 2016 |
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti | 2009 |
Recent cardiovascular trials: what are the drivers of benefit and adverse effect?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetic Angiopathies; Gliclazide; Glycated Hemog | 2009 |
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; | 2007 |